Die JUPITER-Studie: Antworten und Fragen?

Over the last years the indication for a therapy with statins has been expanded. The recently published JUPITER-Trial (Jusfication for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) was conducted to test, if indication for statin therapy can be expanded even further. The study compared rosuvastatin 20 mg daily vs placebo in apparently healthy people with levels of low-density lipoprotein cholesterol (LDL) lower than 130 mg/dL but showed an elevation ( ≥ 2 mg/L) of high-sensitivity C-reactive protein (hs-CRP). Rosuva-statin treatment lowered LDL-C levels by 50% and hs-CRP levels by 37%, accompanied by a 44% relative risk reduction in the composite end point of unstable angina, re-vascularization, and confirmed death from cardiovascular causes. The number-needed-to treat was 95 patients over a 2 year period to prevent one event. We would like to discuss this study with current data on statin therapy and focus on possible implications of the study results.

[1]  J. Liao,et al.  Genetically elevated C-reactive protein and ischemic vascular disease , 2009, Current atherosclerosis reports.

[2]  N. Samani,et al.  Elevated C-reactive protein in atherosclerosis--chicken or egg? , 2008, The New England journal of medicine.

[3]  M. Hellmich,et al.  Multiple biomarkers and cardiovascular risk. , 2008, The New England journal of medicine.

[4]  D. Rader,et al.  The influence of pravastatin and atorvastatin on markers of oxidative stress in hypercholesterolemic humans. , 2008, Journal of the American College of Cardiology.

[5]  E. Topol,et al.  Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. , 2008, JAMA.

[6]  Shah Ebrahim,et al.  European guidelines on cardiovascular disease prevention in clinical practice: executive summary. , 2007, Atherosclerosis.

[7]  Jennifer G. Robinson,et al.  Safety of aggressive lipid management. , 2007, Journal of the American College of Cardiology.

[8]  Deepak L. Bhatt,et al.  A review of high-dose statin therapy: targeting cholesterol and inflammation in atherosclerosis. , 2007, European heart journal.

[9]  Deepak L. Bhatt,et al.  Using statins to treat inflammation in acute coronary syndromes: Are we there yet? , 2006, Cleveland Clinic journal of medicine.

[10]  B. Kasiske,et al.  An assessment of statin safety by nephrologists. , 2006, The American journal of cardiology.

[11]  T. A. Jacobson,et al.  Statin safety: lessons from new drug applications for marketed statins. , 2006, The American journal of cardiology.

[12]  Raimund Erbel,et al.  Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. , 2006, JAMA.

[13]  O. Faergeman,et al.  High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. , 2005, JAMA.

[14]  Jennifer G. Robinson,et al.  Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. , 2005, Journal of the American College of Cardiology.

[15]  R. Collins,et al.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.

[16]  J. Liao.  Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol. , 2005, The American journal of cardiology.

[17]  J. Polak,et al.  C-Reactive Protein and the 10-Year Incidence of Coronary Heart Disease in Older Men and Women: The Cardiovascular Health Study , 2005, Circulation.

[18]  S. Hazen,et al.  Myeloperoxidase and cardiovascular disease. , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[19]  D. Gudbjartsson,et al.  Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial. , 2005, JAMA.

[20]  Philip J. Barter,et al.  Intensive lipid lowering with atorvastatin in patients with stable coronary disease. , 2005, The New England journal of medicine.

[21]  Paul Schoenhagen,et al.  Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. , 2005, The New England journal of medicine.

[22]  M. Pfeffer,et al.  C-reactive protein levels and outcomes after statin therapy. , 2005, The New England journal of medicine.

[23]  Terry A Jacobson,et al.  Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. , 2004, The American journal of cardiology.

[24]  M. Davidson.  Rosuvastatin safety: lessons from the FDA review and post-approval surveillance , 2004, Expert opinion on drug safety.

[25]  Neil J Stone,et al.  Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines , 2004, Circulation.

[26]  S. Hazen,et al.  Inflammatory and oxidative markers in atherosclerosis: Relationship to outcome , 2004, Current atherosclerosis reports.

[27]  E. Topol.  Intensive statin therapy--a sea change in cardiovascular prevention. , 2004, The New England journal of medicine.

[28]  Vilmundur Gudnason,et al.  C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. , 2004, The New England journal of medicine.

[29]  S. Hazen,et al.  Statins Promote Potent Systemic Antioxidant Effects Through Specific Inflammatory Pathways , 2003, Circulation.

[30]  Deepak L. Bhatt,et al.  Using C-reactive protein to assess cardiovascular disease risk. , 2003, Cleveland Clinic journal of medicine.

[31]  E. Topol,et al.  Pharmacogenomics in cardiovascular diseases. , 2003, Progress in cardiovascular diseases.

[32]  Gary L Myers,et al.  Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. , 2003, Circulation.

[33]  Nancy R Cook,et al.  C-Reactive Protein, the Metabolic Syndrome, and Risk of Incident Cardiovascular Events: An 8-Year Follow-Up of 14 719 Initially Healthy American Women , 2003, Circulation.

[34]  J. Tijssen,et al.  Effect of fluvastatin on ischaemia following acute myocardial infarction: a randomized trial. , 2002, European heart journal.

[35]  I. Kushner,et al.  Is high-sensitivity C-reactive protein an effective screening test for cardiovascular risk? , 2002, Archives of internal medicine.

[36]  J. Liao,et al.  Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[37]  N Rifai,et al.  Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. , 2001, JAMA.

[38]  Paul M. Ridker,et al.  Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. , 2001, The New England journal of medicine.

[39]  N Rifai,et al.  High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease. , 2001, Clinical chemistry.

[40]  R. Davidson,et al.  Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. , 2001, The American journal of cardiology.

[41]  P. Ridker,et al.  C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. , 2000, The New England journal of medicine.

[42]  J. M. Bloom.  Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. , 1999, The New England journal of medicine.

[43]  D. Waters,et al.  Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. , 1999, The New England journal of medicine.

[44]  P. Ridker,et al.  Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. , 1998, Circulation.

[45]  A. Gotto,et al.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.

[46]  T. Lancet,et al.  West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials , 1996, The Lancet.

[47]  Michael Marber,et al.  Sensitive troponin I assay in early diagnosis of acute myocardial infarction , 2010 .

[48]  V. Fuster,et al.  Haptoglobin Genotype Is a Determinant of Iron , Lipid Peroxidation , and Macrophage Accumulation in the Atherosclerotic Plaque , 2006 .

[49]  Michael Miller.  Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.

[50]  R. Collins,et al.  The MRC/BHF Heart Protection Study: preliminary results. , 2002, International journal of clinical practice.

[51]  J. Mckenney,et al.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.

[52]  P. Ridker,et al.  High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. , 2001, Circulation.

[53]  P. Ridker.  Novel risk factors and markers for coronary disease. , 2000, Advances in internal medicine.

[54]  M. Pfeffer,et al.  Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. , 1999, Circulation.